The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.
A genetic variation in the 3'-untranslated region of the prothrombin mRNA (20210 G/A) has recently been reported to be associated with elevated plasma prothrombin levels and with an increased incidence of venous thrombosis. We determined the frequency of this mutation, the detection of which was improved by allele-specific amplification of exon 14 and by denaturing gradients (denaturing gradient gel electrophoresis), in cohorts of patients affected by venous thrombosis (n = 132) or by coronary or cerebrovascular diseases (n = 195) and in normal subjects from various populations. An overlapping frequency of the heterozygous genotype (4%) was found in normal subjects from Italy and Cyprus, and no carrier was detected in 40 subjects of Indian or Somali origin. The 20210 GA heterozygous genotype was not increased in frequency in patients with arterial disease. In contrast, the GA genotype was associated (P = .007) with venous thrombosis both in simple heterozygotes (16%) with a family history of thrombosis as well as in double heterozygotes (14%) for other known thrombophilic defects. A synergic interaction between the prothrombin 20210 GA genotype and the factor V Leiden mutation, both potentially affecting the prothrombinase complex, was suggested by the early onset of thrombosis (median age 22 years) in doubly heterozygous patients. The association of the 20210 A allele with higher prothrombin levels was confirmed in the Italian population. However, the prothrombin assay does not allow an efficient preselection of patients for the DNA analysis.
Ferraresi
P
P
Dipartimento di Biochimica e Biologia Molecolare, Università, Ferrara, Italy.
Marchetti
G
G
Legnani
C
C
Cavallari
E
E
Castoldi
E
E
Mascoli
F
F
Ardissino
D
D
Palareti
G
G
Bernardi
F
F
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D000483:Alleles; D002561:Cerebrovascular Disorders / Q000453:epidemiology / Q000235:genetics; D015331:Cohort Studies; D015897:Comorbidity; D003327:Coronary Disease / Q000453:epidemiology / Q000235:genetics; D003535:Cyprus / Q000208:ethnology; D004252:DNA Mutational Analysis; D005006:Ethnicity / Q000235:genetics; D005165:Factor V / Q000032:analysis*; D005260:Female; D005787:Gene Frequency; D006579:Heterozygote; D006801:Humans; D007194:India / Q000208:ethnology; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011516:Prothrombin / Q000235:genetics*; D011644:Puerperal Disorders / Q000453:epidemiology / Q000235:genetics; D011655:Pulmonary Embolism / Q000453:epidemiology / Q000209:etiology; D012998:Somalia / Q000208:ethnology; D019851:Thrombophilia / Q000453:epidemiology / Q000235:genetics*; D013924:Thrombophlebitis / Q000453:epidemiology* / Q000235:genetics
C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin